LIFE

Charles Zhu

Q: How accurate are Charles Zhu's stock ratings?

About 53% of Charles's ratings were profitable over a one-year hold, with an average return of -2.7% per rating, measured by 13Foresight from historical prices.

Q: How is Charles ranked?

Charles Zhu is ranked #2343 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

LifeSci Capital

Wall Street Analyst

★★☆☆☆

#2343

on 13Foresight · ranked by our own returns

53%

Success Rate

-2.7%

Average Return

32 of 60 calls profitable · -7.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 53% of Charles Zhu's ratings turned a profit when each position was held for 1 year — averaging -2.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

193 Buy 6 Hold 0 Sell

Charles's Stock Coverage 23 ratings · 2026-08-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
KURA Kura Oncology	Aug 13, 2026	BUY	Strong Buy +161.3% avg upside 26 analysts	$28.00 181.60% Upside	+0.0%	·
ADAG Adagene	Aug 12, 2026	BUY	Strong Buy +97.1% avg upside 8 analysts	$8.00 113.36% Upside	-1.3%	·
IMNM Immunome	Aug 12, 2026	BUY	Strong Buy +23.6% avg upside 16 analysts	$40.00 42.99% Upside	-5.6%	·
STRO Sutro Biopharma	Aug 12, 2026	BUY	Strong Buy +88.8% avg upside 21 analysts	$54.00 153.48% Upside	+0.1%	·
TARA Protara Therapeutics	Aug 11, 2026	BUY	Strong Buy +1223.0% avg upside 21 analysts	$20.00 414.21% Upside	+0.9%	·
RVMD Revolution Medicines	Aug 08, 2026	BUY	Strong Buy -17.7% avg upside 32 analysts	$291.00 41.86% Upside	-2.4%	·
CNTX Context Therapeutics	Aug 08, 2026	HOLD	Strong Buy +1024.9% avg upside 12 analysts	$2.00 325.66% Upside	+4.4%	·
IDYA IDEAYA Biosciences	Aug 08, 2026	BUY	Strong Buy +31.3% avg upside 29 analysts	$58.00 56.88% Upside	-0.2%	·
ZYME Zymeworks	Aug 06, 2026	BUY	Strong Buy +34.5% avg upside 25 analysts	$34.00 36.34% Upside	+5.1%	·
CMPX Compass Therapeutics	Aug 06, 2026	BUY	Strong Buy +317.5% avg upside 20 analysts	$6.00 153.25% Upside	+13.6%	·
RCUS Arcus Biosciences	Aug 05, 2026	BUY	Strong Buy +23.2% avg upside 20 analysts	$46.00 58.75% Upside	+3.9%	·
CBIO Crescent Biopharma	Jul 30, 2026	BUY	Strong Buy +35.2% avg upside 17 analysts	$28.00 70.47% Upside	+12.1%	·
PBLS Parabilis Medicines, Inc.	Jul 18, 2026	BUY	Strong Buy +20.6% avg upside 6 analysts	$42.00 12.32% Upside	+28.1%	·
MOLN Molecular Partners	Jul 11, 2026	BUY	Strong Buy +142.1% avg upside 7 analysts	$12.00 190.65% Upside	+1.0%	·
GYRE Gyre Therapeutics	Jun 18, 2025	BUY	Strong Buy +209.6% avg upside 15 analysts	$22.00 230.26% Upside	-25.0%	·
TNGX Tango Therapeutics	May 24, 2024	BUY	Strong Buy +51.0% avg upside 15 analysts	$14.00 45.23% Downside	-73.4%	·
MGNX MacroGenics	Jan 02, 2024	BUY	Buy +339.8% avg upside 25 analysts	$20.00 397.45% Upside	-67.6%	·
COGT Cogent Biosciences	Jun 13, 2023	BUY	Strong Buy -4.5% avg upside 26 analysts	$26.00 33.39% Downside	-30.1%	·
XNCR Xencor	May 09, 2023	BUY	Strong Buy +50.6% avg upside 27 analysts	$39.00 68.31% Upside	-12.3%	·
TRAW Traws Pharma	Mar 17, 2023	BUY	Buy +5808.8% avg upside 10 analysts	$5.00 837.83% Upside	+3.8%	·
NGNE Neurogene	Jan 03, 2023	HOLD	Strong Buy +32.6% avg upside 23 analysts	—	+93.8%	·
PMVP PMV Pharmaceuticals	Jan 03, 2023	BUY	Strong Buy +1051.7% avg upside 12 analysts	$20.00 1487.25% Upside	-65.1%	·
TSE:MDNA Medicenna Therapeutics Corp	Nov 29, 2022	BUY	Strong Buy +1102.7% avg upside 9 analysts	$2.00 393.90% Upside	-23.0%	·

🔒 18 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Charles Zhu — Frequently Asked Questions

How accurate are Charles Zhu's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Charles's ratings were profitable over a one-year hold, with an average return of -2.7% per rating, or -7.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Charles ranked on 13Foresight?

Charles Zhu is currently ranked #2343 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Charles cover?

Charles most recently has ratings on KURA, ADAG, IMNM, STRO, TARA, RVMD, CNTX, IDYA, ZYME, CMPX, RCUS, CBIO and 11 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Charles Zhu

Rating Distribution

Welcome to 13Foresight!